IMUGENE CHART. TA only, page-12843

Imugene has “enviable cash runway” says Roth Capital Partners, placing 'buy' recommendation on cancer therapy biotech

Imugene Ltd (ASX:IMU, OTC:IUGNF)’s recent clinical activities – including brokering partnerships and securing patents – along with a well-funded cash position, have prompted Roth Capital Partners to place a 'buy' recommendation on the clinical-stage oncology company.
The company started the year with A$118.4 million, enough to fund operations for almost four years, and an “enviable cash runway”. It has also accomplished a great deal in the clinical space over the eight months to the first half of this financial year.
Price target maintained

“Our 12-month price target of A$0.71 is based on a DCF analysis using a 15% discount rate that is applied to all cash flows and the terminal value, which is based on a 6x multiple of our projected FY2031 operating income of about A$1.47 billion,” said the Roth Capital Partners report.
“We arrive at this valuation by projecting future revenue from CHECKvacc in TNBC, HER-Vaxx in advanced HER2+ gastric cancer, and PD1-Vaxx in NSCLC.
"Commercial success outside these financially modelled programs would serve as potential upside to our valuation."